New shot aims to cure hepatitis b without daily pills

NCT ID NCT07246889

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests an experimental drug called AHB-137 in 577 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral pills. Participants receive weekly injections of AHB-137 or a placebo for a set period, then stop all hepatitis B treatment. The main goal is to see if the virus stays undetectable 24 weeks after stopping all therapy, which would mean a functional cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AHB-137 injection (an experimental drug) given weekly under the skin, plus standard nucleoside analogue therapy

What this could lead to

If successful, this could offer a way to stop long-term antiviral pills and achieve a 'functional cure' where the virus is undetectable without ongoing medication.

What could go wrong

This is still an early-phase 3 trial, so results may not confirm benefit. There is a risk of side effects from the injection or that the virus returns after stopping treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AusperBio Investigational Site

    Hefei, Anhui, China

  • AusperBio Investigational Site

    Beijing, Beijing Municipality, China

  • AusperBio Investigational Site

    Chongqing, Chongqing Municipality, China

  • AusperBio Investigational Site

    Fuzhou, Fujian, China

  • AusperBio Investigational Site

    Xiamen, Fujian, China

  • AusperBio Investigational Site

    Lanzhou, Gansu, China

  • AusperBio Investigational Site

    Foshan, Guangdong, China

  • AusperBio Investigational Site

    Guangzhou, Guangdong, China

  • AusperBio Investigational Site

    Shenzhen, Guangdong, China

  • AusperBio Investigational Site

    Liuzhou, Guangxi, China

  • AusperBio Investigational Site

    Nanning, Guangxi, China

  • AusperBio Investigational Site

    Guiyang, Guizhou, China

  • AusperBio Investigational Site

    Zunyi, Guizhou, China

  • AusperBio Investigational Site

    Haikou, Hainan, China

  • AusperBio Investigational Site

    Zhengzhou, Henan, China

  • AusperBio Investigational Site

    Wuhan, Hubei, China

  • AusperBio Investigational Site

    Changsha, Hunan, China

  • AusperBio Investigational Site

    Nanjing, Jiangsu, China

  • AusperBio Investigational Site

    Zhenjiang, Jiangsu, China

  • AusperBio Investigational Site

    Nanchang, Jiangxi, China

  • AusperBio Investigational Site

    Changchun, Jilin, China

  • AusperBio Investigational Site

    Shenyang, Liaoning, China

  • AusperBio Investigational Site

    Shanghai, Shanghai Municipality, China

  • AusperBio Investigational Site

    Taiyuan, Shanxi, China

  • AusperBio Investigational Site

    Xi’an, Shanxi, China

  • AusperBio Investigational Site

    Chengdu, Sichuan, China

  • AusperBio Investigational Site

    Kunming, Yunnan, China

  • AusperBio Investigational Site

    Hangzhou, Zhejiang, China